Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Larisa Bolotina"'
Autor:
Anna Kornietskaya, Sevindzh Evdokimova, Andrei Kachmazov, Alexander. Fedenko, Larisa Bolotina, Dmitriy Sidorov, Nadezhda Volchenko, Natalia Goeva, Anastasia Govaleshko, Andrey Kaprin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare tumor, associated with favorable prognosis and long-term survival in patients with advanced disease. However, limited data exist on systemic therapy for such patients. Herein,
Externí odkaz:
https://doaj.org/article/02b777128c3f4e2ab4418068bf7b92c3
Autor:
Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various
Externí odkaz:
https://doaj.org/article/15215176b97f49e896e659eee237e11e
Autor:
Andrey Poloznikov, Sergey Nikulin, Larisa Bolotina, Andrei Kachmazov, Maria Raigorodskaya, Anna Kudryavtseva, Ildar Bakhtogarimov, Sergey Rodin, Irina Gaisina, Maxim Topchiy, Andrey Asachenko, Victor Novosad, Alexander Tonevitsky, Boris Alekseev
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Colorectal cancer (CRC) is one of the most common and lethal types of cancer. Although researchers have made significant efforts to study the mechanisms underlying CRC drug resistance, our knowledge of this disease is still limited, and novel therapi
Externí odkaz:
https://doaj.org/article/b45386e93e1c4e5eaaa4f3c1e8c40e9f
Publikováno v:
World Journal of Oncology. 14:26-31
Autor:
Inna P. Ganshina, Elena G. Ovchinnikova, Oksana M. Shalaeva, Svetlana V. Kuzmicheva, Alina N. Fedorova, Asiat I. Tekeeva, Alexander V. Sultanbaev, Elena V. Markizova, L G Zhukova, Ksenia S. Maistrenko, Svetlana A. Orlova, Irina V. Evstigneeva, Daniil L'vovich Stroyakovskiy, James J. Kolokolov, Olesya A. Kuchevskaya, Oksana N. Shirokova, Oksana I. Arapova, Elena V. Zueva, Anna V. Vasilevskaya, Tatyana A. Nersesova, Arshak A. Akopyan, Irina V. Kolyadina, Larisa Bolotina, Mariam Z. Yakubova, Sergey P. Medvedev, Alexandr S. Dergunov, Irina A. Shangina, Elvira A. Bobrova, Chulpan K. Valiakhmetova, Anna E. Storozhakova, Aleksei V. Emshanov, Natalia V. Fadeeva, Mikhail V. Volkonskiy, Yulia I. Merzlikina, Galina V. Antonova, Ivan A. Luev, Alisa R. Shumskikh, Natalia Yu. Samaneva, Elena Karabina, Natalia R. Abidova, Viktoria S. Egurenkova, Vasily V. Marfutov, Irina E. Gudkova, Lyubov Vladimirova, Olesya A. Stativko
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 68-76 (2021)
Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinica
Autor:
M. B. Stenina, R. V. Orlova, E. V. Artamonova, Larisa Bolotina, M. A. Mukhina, E. I. Kovalenko
Publikováno v:
Opuholi Ženskoj Reproduktivnoj Sistemy, Vol 16, Iss 3, Pp 37-45 (2021)
The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by rand
Autor:
S. A. Borozdina, Nikita M. Volkov, Larisa Bolotina, A. A. Vakhitova, A. A. Paichadze, A. N. Poltoratsky, Boris Kasparov, O. E. Ryabishina, Fedor Moiseenko, M.L. . Stepanova, A. A. Kachmazov, T. Yu. Semiglazova, A. V. Avramenko, Evgeny N. Imyanitov, E. V. Artemeva, Sh. A. Dzhalilova, A. I. Kornietskaya, Ludmila Zhukova, E. V. Lubennikova, A. A. Meshcheryakov, Veronika Klimenko, Rashida Orlova, I. P. Ganshina
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 143-146 (2020)
Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of
Autor:
M. Yu. Fedyanin, L. A. Zagorskaya, O. L. Fakhrutdinova, O. V. Nekrasova, S. A. Belukhin, A. A. Mishchenko, L. Yu. Vladimirova, Alfia Khasanova, B. Kh. Kertiev, Ye. V. Karabina, A. K. Ivanova, A. V. Belyayeva, Viacheslav Chubenko, A. V. Androsova, Alexey Tryakin, P S Feoktistova, Rashida Orlova, Guzel Mukhametshina, S. N. Osodoyeva, R. R. Malina, I. A. Pokatayev, O. Yu. Novikova, L. V. Khalikova, V. M. Sherstnev, A. A. Meshcheryakov, Sanal Erdniev, Elena Artamonova, Kh. S. Musayeva, Irina L. Popova, L. A. Mukova, Larisa Bolotina, F. V. Moiseyenko, A. I. Katz, Ye. S. Kuzmina, G. I. Kosar, I. Yu. Stradayeva, Vladimir Moiseyenko, S. A. Tyulyandin, A S Zhabina, A. Belonogov
Publikováno v:
Malignant tumours. 9:53-63
Purpose. To assess the incidence and severity of adverse events; to explore clinical factors associated with grade 3–4 non-hematologic toxicity; to assess the immediate efficacy and progression-free survival during treatment with the FOLFIRI regime
Autor:
Valerii V. Breder, Larisa Bolotina, Bela M. Medvedeva, D.T. Abdurakhmanov, Vladislav V Petkau, Vladislav Iu Kosyrev
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 10-16 (2019)
Hepatocellular carcinoma (HCC) is the most common liver malignancy and ranks sixth for cancer prevalence and fourth place among the causes of cancer mortality. Despite the improvement of diagnostic techniques, the diagnosis of HCC is still determined
Autor:
Mikhail A Osipov, Iuliia V Kostalanova, Elena Karabina, Vera A Gorbunova, Dmitrii M Ponomarenko, Evgeniia S Kuz'mina, Al'fiia I Khasanova, Elena M Cherniakova, Natalia V Strakhova, Tat'iana V Karandeeva, Natal'ia V Levchenko, Inna P. Ganshina, Guzel' Z Mukhametshina, S V Khokhlova, Mikhail V Shaidorov, Tat'iana Iu Semiglazova, Irina S Bulavina, Liubov' I Vladimirova, Elena V. Artamonova, Dzheims Dzh Kolokolov, Il'ia M Itkin, Alina S Shatokhina, Aleksei G Manikhas, Larisa Bolotina, Natal'ia A Raevskaia, Igor' S Chernov, Oksana N Shkodenko, Dmitrii V Filonenko, N. O. Popova, V E Goldberg, Natal'ia M Tikhanovskaia, Irina V. Kolyadina, Sufiia Z Safina, Andrei E Orlov, Liudmila V Manziuk, Valentina E Shikina, Liudmila G. Zhukova, Irina V. Evstigneeva, Anton Iu Povyshev, Elena I. Kovalenko, Vladislav V Petkau
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 17-24 (2019)
Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials